Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated Rejection

Launched by HOSPICES CIVILS DE LYON · May 16, 2019

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a medication called Everolimus for kidney transplant patients who are experiencing a specific type of rejection known as "missing self" rejection. This type of rejection is caused by natural killer (NK) cells in the immune system detecting that certain markers (called MHC class I molecules) are not present on the transplanted kidney. The trial aims to see if using Everolimus, along with other medications, can help improve kidney function and reduce damage caused by this rejection.

To participate in the trial, patients must be over 18 years old, have received a kidney transplant, and show signs of inflammation in their kidney biopsy without having specific antibodies that could indicate a different type of rejection. During the trial, participants will take Everolimus for six months, and their kidney function and overall health will be closely monitored. This study is currently recruiting participants, and it could offer new treatment options for patients facing challenges with their transplanted kidneys.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient aged \> 18 years
• • Kidney transplanted patient
• • Having microvascular inflammation lesion on his graft biopsy associated to mild chronic lesions
• • In absence of donor specific antibodies
• • In presence of a missing self
• Exclusion Criteria:
• • Proteinuria/urinary creatinin \> 100 mg/mmol
• • Antecedent of poor tolerance or hypersensibility to everolimus or sirolimus
• • Severe chronic lesions
• • Presence of donor specific antibodies